SCHEMBL19626342

SCHEMBL19626342

Cc1ccc(C2C[C@]23CCNC3)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 5/20 0.37
SLC6A4 P31645 5/20 0.37
SLC6A3 Q01959 5/20 0.37
KCNH2 Q12809 1/20 0.37
MAPT P10636 1/20 0.35
OPRM1 P35372 2/20 0.34
ADCY5 O95622 1/20 0.33
GABRD O14764 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRB1 P18505 1/20 0.32
GABRA5 P31644 1/20 0.32
GABRA3 P34903 1/20 0.32
GABRA2 P47869 1/20 0.32
GABRB2 P47870 1/20 0.32
GABRA4 P48169 1/20 0.32
PRCP P42785 1/20 0.32
HTR2A P28223 2/20 0.32
HTR2C P28335 1/20 0.32
HTR2B P41595 1/20 0.32
SLC6A9 P48067 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20840859 1.00 SLC6A2 (0.37) SLC6A2SLC6A4SLC6A3KCNH2MAPT
SCHEMBL19626470 0.90 SLC6A2 (0.36) SLC6A2SLC6A4SLC6A3KCNH2MAPT
SCHEMBL19626472 0.90 SLC6A2 (0.36) SLC6A2SLC6A4SLC6A3KCNH2MAPT
SCHEMBL21418971 0.83 LIG1 (0.42) SLC6A2SLC6A4SLC6A3KCNH2OPRM1
SCHEMBL21418957 0.83 LIG1 (0.42) SLC6A2SLC6A4SLC6A3KCNH2OPRM1
SCHEMBL23466168 0.83 LIG1 (0.42) SLC6A2SLC6A4SLC6A3KCNH2OPRM1
SCHEMBL21836832 0.83 LIG1 (0.42) SLC6A2SLC6A4SLC6A3KCNH2MAPT
SCHEMBL17725137 0.83 LIG1 (0.42) SLC6A2SLC6A4SLC6A3KCNH2OPRM1
SCHEMBL17725393 0.83 LIG1 (0.42) SLC6A2SLC6A4SLC6A3KCNH2OPRM1
SCHEMBL19629557 0.83 LIG1 (0.42) SLC6A2SLC6A4SLC6A3KCNH2OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10000477-B2 Dopamine D3 receptor antagonist compounds INDIVIOR UK LIMITED (GB) 2018-06-19 US disclosed
US-20170334895-A1 DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS INDIVIOR INC. 2017-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10000477-B2 Dopamine D3 receptor antagonist compounds DRD3, DRD2, DRD4 SLC6A2 106/4885SLC6A4 181/4885SLC6A3 5/4885
US-20170334895-A1 DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS DRD3, DRD2, DRD4 SLC6A2 106/4885SLC6A4 181/4885SLC6A3 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.